Business Description
Unicycive Therapeutics Inc
NAICS : 325110
SIC : 2834
ISIN : US90466Y2028
Share Class Description:
UNCY: Ordinary SharesTotal Employee Number:
22Description
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 58.01 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 48.4 | |||||
3-Year EPS without NRI Growth Rate | 46.9 | |||||
3-Year FCF Growth Rate | 42.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.53 | |||||
9-Day RSI | 39.24 | |||||
14-Day RSI | 40.57 | |||||
3-1 Month Momentum % | 4.33 | |||||
6-1 Month Momentum % | 24.66 | |||||
12-1 Month Momentum % | 55.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.4 | |||||
Quick Ratio | 2.4 | |||||
Cash Ratio | 2.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -144 | |||||
Shareholder Yield % | -40.62 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -150.09 | |||||
ROA % | -89.94 | |||||
ROIC % | -203.61 | |||||
3-Year ROIIC % | -67.79 | |||||
ROC (Joel Greenblatt) % | -8212.02 | |||||
ROCE % | -149.64 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 10.17 | |||||
PB Ratio | 3.84 | |||||
Price-to-Tangible-Book | 3.85 | |||||
EV-to-EBIT | -2.59 | |||||
EV-to-EBITDA | -2.63 | |||||
EV-to-Forward-Revenue | 10.89 | |||||
EV-to-FCF | -3.6 | |||||
| Price-to-Net-Current-Asset-Value | 3.92 | |||||
| Price-to-Net-Cash | 5.21 | |||||
Earnings Yield (Greenblatt) % | -38.61 | |||||
FCF Yield % | -18.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UNCY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Unicycive Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.21 | ||
| Beta | 0.5322 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 61.81 | ||
| 14-Day RSI | 40.57 | ||
| 14-Day ATR ($) | 0.903752 | ||
| 20-Day SMA ($) | 7.081 | ||
| 12-1 Month Momentum % | 55.82 | ||
| 52-Week Range ($) | 3.71 - 8.74 | ||
| Shares Outstanding (Mil) | 27.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Unicycive Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Unicycive Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 42 days | ||
| General meeting for 2026 | 2026-06-19 10:00 | 6.85 (-4.86%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 7.95 (-1.24%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 15:45 | 6.94 (+3.58%) | ||
| Annual report for 2025 | 2026-03-30 | 6.39 (-2.74%) | ||
| Guggenheim Emerging Outlook: Biotech Summit | 2026-02-11 13:30 | 6.37 (-3.48%) | ||
| Noble Capital Markets Virtual Presentation | 2025-12-10 10:00 | 6.52 (-0.31%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-03 10:00 | 5.86 (-3.30%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 4.79 (+2.13%) |
Show
Entries
Unicycive Therapeutics Inc Frequently Asked Questions
What is Unicycive Therapeutics Inc(UNCY)'s stock price today?
The current price of UNCY is $5.73. The 52 week high of UNCY is $8.74 and 52 week low is $3.71.
When is next earnings date of Unicycive Therapeutics Inc(UNCY)?
The next earnings date of Unicycive Therapeutics Inc(UNCY) is 2026-08-14 Est..
Does Unicycive Therapeutics Inc(UNCY) pay dividends? If so, how much?
Unicycive Therapeutics Inc(UNCY) does not pay dividend.
Guru Commentaries on NAS:UNCY
No articles.
Press Release
Articles on Unicycive Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 30, 2026
Unicycive plummets following second CRL for OLC for hyperphosphatemia
Seeking Alpha • 1:05pm
Jun 22, 2026
Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market
Seeking Alpha • 8:56am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers